Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares changing hands.
Hemispherx BioPharma Stock Down 20.0%
The business’s fifty day moving average is $6.70 and its 200 day moving average is $6.70.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
Read More
- Five stocks we like better than Hemispherx BioPharma
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
- My Epstein Story
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
